Clinical Experience with Genotropin Worldwide: An Update March 1987

ABSTRACT. Gunnarsson, R., and Wilton, P. (Medical Department, KabiVitrum Peptide Hormones, Stockholm, Sweden). Clinical experience with Genotropin worldwide: an update March 1987. Acta Paediatr Scand [Suppl] 337:147, 1987. The efficacy and safety of Genotropin (recombinant somatropin, KabiVitrum AB, Sweden) was analysed in 199 children with hGH deficiency, comprising a combined series of four current multicentre trials. Stimulation of linear growth from pretreatment height velocities of 3–4 cm/year to about 10 cm/year was observed after 6 and 9 months of treatment. Statistical analysis revealed significantly greater height velocities (by 2–3 cm/year) when the weekly dose of the hormone was given in 6–7 injections rather than in 3 injections. Immunogenicity seems to be very low, with only about 2% of the children having detectable antibodies during treatment.